• EDITORIAL POLICY
  • ABOUT US
PML Daily
No Result
View All Result
  • Home
  • NEWS
    • Politics
    • Education
    • Regional
    • Africa
    • World
  • INVESTIGATIONS
    • National Archives
    • Special Reports
  • OpEd
  • BUSINESS
    • Agriculture
    • Tech
    • Finance
  • FEATURES
    • Health
    • Tours & Travel
    • Entertainment
    • Society
  • COLUMNISTS
    • The Suited Penguin
  • SPORT
  • Jobs
  • Magazines
  • Home
  • NEWS
    • Politics
    • Education
    • Regional
    • Africa
    • World
  • INVESTIGATIONS
    • National Archives
    • Special Reports
  • OpEd
  • BUSINESS
    • Agriculture
    • Tech
    • Finance
  • FEATURES
    • Health
    • Tours & Travel
    • Entertainment
    • Society
  • COLUMNISTS
    • The Suited Penguin
  • SPORT
  • Jobs
  • Magazines
No Result
View All Result
PML Daily
No Result
View All Result
Home FEATURES Health

Govt gives Gulu University UGX. 3.7bn for Covilyce-1 clinical trial

NELSON MANDELA | PML Daily ReporterbyNELSON MANDELA | PML Daily Reporter
July 15, 2021
101 2
74
SHARES
1.5k
VIEWS
FacebookWhatsAppTwitter
Covilyce 1, Coronavirus herbal drug pending approval (PHOTO/Courtesy).

KAMPALA – The government has provided Gulu University a sum of Shs3.7 billion to test Covylice-1, another herbal drug that reportedly heals Covid-19 within 72 hours.

Covilyce-1 was created by scientists at Gulu University Faculty of Biotechnology and Pharmaceutical Studies (Pharm-Biotech) led by Dr Alice Lamwaka.

This was after the innovators being stopped from trading the drug by the National Drug Authority – NDA on grounds that it was still under research and development.

It is said that NDA asked the drug developers to disclose the plants they used to make the medicine, and the formulation process as one of the requirements for approval.

However, the University rejected NDA’s demand.

The scientist say their medicine has so far “cured” 100 people before clinical trials.

According to the sources, NDA wants the university to declare the contents of the drug by naming the details of each plant, as well as declare how they formulate it so that they are sure of the product being made.

According to Daily Monitor, Dr Lamwaka confirmed that NDA has set for them those conditions.

“But we told the team we cannot name the plants because Covilyce-1 is still a lab-based product, which is not officially in the market,” Dr Lamwaka said.

“We withheld the botanical names of plants used in formulating Covilyce-1 but we accepted to only name the active ingredients and what parts of the plants have been used to develop Covilyce-1,” Dr Lamwaka added.

However, Mr James Onono, the university spokesperson, who also attended the meeting, said they agreed to submit the application to NDA for Covylice-1 approval but that they will not reveal names of the plants.

NDA said the university has confirmed to them that the product was still under lab research and tests, and that “before we notify a product, it shouldn’t be used as we can’t guarantee its safety.”

Related

Leave a comment

Tags: Covid-19 cureCovid-19 herbal drugDr Alice Lamwakagulu universityNational Drug Authoritytop

Get real time update about this post categories directly on your device, subscribe now.

Unsubscribe

Advertisement

About

The PML Daily, published via www.pmldaily.com is a publication of Post Media Ltd, a professional Digital/New Media company in Uganda.

Follow us



  • EDITORIAL POLICY
  • ABOUT US

© 2022

No Result
View All Result
  • Home
  • NEWS
    • Politics
    • Education
    • Regional
    • Africa
    • World
  • INVESTIGATIONS
    • National Archives
    • Special Reports
  • OpEd
  • BUSINESS
    • Agriculture
    • Tech
    • Finance
  • FEATURES
    • Health
    • Tours & Travel
    • Entertainment
    • Society
  • COLUMNISTS
    • The Suited Penguin
  • SPORT
  • Jobs
  • Magazines

© 2022

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist